Compare GSK plc (GSK) vs Unilever plc (UL) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Unilever (UL) trades at $62.49, up 2.71% with a bullish technical signal. Recent earnings misses contrast with strong profitability margins and a 53.32% ROE. The company is divesting its food business to McCormick and investing in innovation, while maintaining a $0.54 dividend. Cash flow improved to $1.91B net in 2024 after a volatile period.

Outlook remains mixed: valuation appears fair with a P/E of 20.83, but revenue declines and execution risks on strategic deals pose challenges. Analyst sentiment is cautious with only 24% buy ratings. The stock offers stability through dividends but faces headwinds in sales growth and competitive pressures.